Translation and Linguistic Validation of the Simplified Chinese Brain Cancer Patient-Reported Outcomes Evaluation System

2020 ◽  
Author(s):  
Chaohong Zhan ◽  
Honghui Yao ◽  
Gelei Xiao ◽  
Zhi Tang ◽  
Ye Liang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Therapy ◽  
Cancer Patients ◽  
Functional Assessment ◽  
Brain Cancer ◽  
Evaluation System ◽  
Measurement Theory ◽  
Patient Reported ◽  
Conceptual Equivalence

Abstract BackgroundThe Functional Assessment of Cancer Therapy Scale Brain Cancer-Specific Module (FACT-Br) was developed by a standard measurement theory and used to assess the symptoms, functions, and quality of life among brain cancer patients in English spoken countries. However, this instrument has not been translated into Chinese.ObjectiveThis study aimed to develop the Chinese version of the Functional Assessment of Cancer Therapy Scale Brain Cancer-Specific Module (C-FACT-Br).MethodsC-FACT-Br was translated following the standard Functional Assessment of Chronic Illness Therapy Translation (FACIT) methodology. Then, the cognitive briefing interviews were done to ensure the conceptual equivalence by probing 10 native Chinese-speaking brain cancer patients.ResultsThe translation was finished by bilingual teams with the help of the FACIT organization. All items in C-FACT-Br were understandable to patients, and they also gave some comments in adjusting items in scale.ConclusionsC-FACIT-Br items had the equivalence meaning, same structure, and harmonization with the English version. Brain cancer patients over 18 years old can understand the scale and express their symptoms, function, and quality of life by these measures.

scholarly journals Acupuncture for Breast Cancer: A Systematic Review and Meta-Analysis of Patient-Reported Outcomes

2021 ◽  
Vol 11 ◽  
Author(s):  
Yuzhu Zhang ◽  
Yang Sun ◽  
Dongmei Li ◽  
Xiaoyuan Liu ◽  
Chen Fang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Systematic Review ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Patient Reported Outcomes ◽  
Meta Analysis ◽  
Hot Flashes ◽  
Patient Reported

AbstractThe present systematic review and meta-analysis was undertaken to evaluate the effects of acupuncture in women with breast cancer (BC), focusing on patient-reported outcomes (PROs).MethodsA comprehensive literature search was carried out for randomized controlled trials (RCTs) reporting PROs in BC patients with treatment-related symptoms after undergoing acupuncture for at least four weeks. Literature screening, data extraction, and risk bias assessment were independently carried out by two researchers.ResultsOut of the 2, 524 identified studies, 29 studies representing 33 articles were included in this meta-analysis. At the end of treatment (EOT), the acupuncture patients’ quality of life (QoL) was measured by the QLQ-C30 QoL subscale, the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES), the Functional Assessment of Cancer Therapy–General/Breast (FACT-G/B), and the Menopause-Specific Quality of Life Questionnaire (MENQOL), which depicted a significant improvement. The use of acupuncture in BC patients lead to a considerable reduction in the scores of all subscales of the Brief Pain Inventory-Short Form (BPI-SF) and Visual Analog Scale (VAS) measuring pain. Moreover, patients treated with acupuncture were more likely to experience improvements in hot flashes scores, fatigue, sleep disturbance, and anxiety compared to those in the control group, while the improvements in depression were comparable across both groups. Long-term follow-up results were similar to the EOT results.ConclusionsCurrent evidence suggests that acupuncture might improve BC treatment-related symptoms measured with PROs including QoL, pain, fatigue, hot flashes, sleep disturbance and anxiety. However, a number of included studies report limited amounts of certain subgroup settings, thus more rigorous, well-designed and larger RCTs are needed to confirm our results.

Investigation of the validity and reliability of the Turkish version of the Functional Assessment of Cancer Therapy—Cognitive Function in cancer patients

2021 ◽  
pp. 1-7
Author(s):  
Songül Atasavun Uysal ◽  
Vesile Yildiz Kabak ◽  
Yusuf Karakas ◽  
Erdem Karabulut ◽  
Deniz Erdan Kocamaz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cognitive Function ◽  
Cancer Therapy ◽  
Cancer Patients ◽  
Functional Assessment ◽  
Cognitive Functions ◽  
Validity And Reliability ◽  
Turkish Version ◽  
Eortc Qlq

Abstract Objective The Functional Assessment of Cancer Therapy—Cognitive Function (FACT-Cog) is a questionnaire that is used to evaluate the quality of life and cognitive functions according to individual self-reports. The aim of this study was to investigate the validity and reliability of the Turkish version of the FACT-Cog. Methods Cancer patients who were treated with chemo or radiotherapy and had a score of 24/30 and more in Mini-Mental State Examination (MMSE) were included in this study. Cognitive functions assessed with the FACT-Cog and the European Organization of Research and Treatment of Cancer Quality of Life Core Questionnaire Core 30: Cognitive Function subscale (EORTC QLQ-CF). Results One hundred and forty cancer patients [female = 87 (62.1%), male = 53 (37.9%)] were included. The mean age of the participants was 47.93 ± 11.90 years. The Cronbach's α of the FACT-Cog scale was 0.82. Test–retest intraclass correlation coefficient values of the FACT-Cog questionnaire were varied from 0.855 to 0.954. There were found low correlations between the total score of the FACT-Cog and the MMSE (r = 0.26, p = 0.002), and moderate correlations between the EORTC QLQ-CF subscale and the FACT-Cog (r = −0.43; p < 0.001). Significance of results It showed the validity and reliability of the Turkish version of the FACT-Cog questionnaire for cancer patients. It may be beneficial to use this questionnaire for the effects of cancer treatment.

Cancer-related pain and quality of life in prostate cancer patients: Assessment using the Functional Assessment of Prostate Cancer Therapy

2009 ◽  
Vol 16 (5) ◽  
pp. 522-525 ◽  
Author(s):  
Tetsuya Fujimura ◽  
Satoru Takahashi ◽  
Haruki Kume ◽  
Takumi Takeuchi ◽  
Tadaichi Kitamura ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Therapy ◽  
Cancer Patients ◽  
Functional Assessment ◽  
Prostate Cancer Therapy

Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 346-346 ◽  
Author(s):  
David Cella ◽  
Michelle Denise Hackshaw ◽  
Jose Diaz ◽  
Chun Huang ◽  
Keith C. Deen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Analysis Of Covariance ◽  
Phase Iii ◽  
Life Questionnaire ◽  
Patient Reported ◽  
Hands And Feet ◽  
Over Time

346 Background: Pazopanib and sunitinib are targeted therapies associated with particular treatment-related side effects that may affect patients’ QoL. COMPARZ was a randomized, open-label, parallel group, phase III study of pazopanib vs. sunitinib in 1,110 subjects with advanced RCC who had not received prior systemic therapy. The study demonstrated pazopanib is non-inferior to sunitinib with respect to progression-free survival. The study also confirmed the differentiated safety profiles of the two drugs. Methods: QoL endpoints were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), the Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 (FKSI-19), the Cancer Therapy Satisfaction Questionnaire (CTSQ), and a Supplementary Quality of Life Questionnaire (SQLQ). Research to validate the SQLQ is currently ongoing. Each instrument was administered at baseline (except CTSQ) and then day 28 of every cycle. Changes in mean scores over time were analyzed and compared using a repeated measures analysis of covariance. Comparisons were pre-specified at the first 6 months of treatment as this time was expected to be a key interval during which tolerability issues may have occurred. Results: During the first 6 months, treatment differences in change from baseline for 11 of the 14 QoL domains studied were statistically significant (p < 0.05), all of which favored pazopanib. Further analysis up to 12 months of treatment, showed the treatment differences observed for fatigue scores increased over time with pazopanib improving and sunitinib remaining relatively flat. The difference in limitations due to foot soreness between the two treatments also progressively increased with time over 12 months favoring pazopanib. Conclusions: In this study, better patient-reported QoL scores for pazopanib indicate subjects experienced less worsening of fatigue, as well as mouth/throat, hands, and feet soreness, and fewer limitations due to soreness, while on pazopanib compared with sunitinib. The differences observed are likely to be clinically meaningful. The FACIT-F and SQLQ results are also highly consistent with the previously-reported PISCES study.

Sign in / Sign up

Export Citation Format

Share Document